Acura Pharmaceuticals Inc. (ACUR)

[The Rainmaker]

First 3 months Egalet sold as much Oxaydo as Pfizer did in 18 months. Good move switching to Egalet.

Turning to OXAYDO, our FDA approved AVERSION Technology opioid product marketed by Egalet. Egalet launched the product in the US in the third quarter of 2015 with commercial product distribution commencing early in the fourth quarter. Egalet is promoting OXAYDO with 50 sales reps targeting about 7,000 high opioid prescribing physicians.

We understand Egalet is currently planning a 21-rep sales force expansion in 2016. Egalet has also put in place a co-pay assistance program for all commercially insured patients receiving an OXAYDO prescription will be eligible to pay no more than $15 per prescription. We don't want to get out in front of Egalet on their discussions of OXAYDO. So we invite you to listen to their earnings call on March 8 at 8:30 AM. For more information visit Egalet.com.

We are still early in the OXAYDO launch. The distribution system which can be challenging for Schedule II narcotics is still being developed, and most doctors are getting their first exposure to OXAYDO. The numbers here are small, but growing. However, we donote that in the fourth quarter of 2015, that is the first quarter that Egalet has marketed OXAYDO, according to IMS data, the retail dispensed tablets for OXAYDO was approximately the same as the dispensed tablets achieved by our previous partner Pfizer in their first year and a half of marketing. We believe this reaffirms our decision to take the product back from Pfizer and find a more motivated partner.